Why the study?
Does long-acting propranolol provide effective beta-blockade and clinical efficacy comparable to conventional propranolol in patients with angina, hypertension, or hyperthyroidism?
Does long-acting propranolol provide effective beta-blockade and clinical efficacy comparable to conventional propranolol in patients with angina, hypertension, or hyperthyroidism?
Long-acting propranolol offers a simplified once-daily dosing regimen that maintains 24-hour beta-blockade and clinical efficacy comparable to standard formulations.
May support once-daily propranolol dosing; leaves open confirmation in contemporary randomized trials.
Long-acting propranolol (Inderal LA) is a new formulation of propranolol that allows release of the drug in a controlled manner, so that the plasma concentration at 24 hr after dosing is greater with long-acting propranolol than with conventional tablets. A single dose of 160 mg of long-acting propranolol can produce cardiac beta-adrenoceptor blockade throughout a 24 hr period without variability due to multiple peak concentrations. It has been shown that this formulation is as effective in the treatment of angina pectoris, hypertension and hyperthyroidism as the standard formulation. Studies with long-acting propranolol in cardiac dysrhythmias are lacking. This new dosage form would be a means of simplifying dosing regimens and thereby hopefully enhancing patient convenience and compliance.
No takes yet. Share an insight, caveat, or question.
Mishriki et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: